Abstract
Membrane proteins are the largest group of therapeutic targets in a variety of disease areas and yet, they remain particularly difficult to investigate. We have developed a novel one-step approach for the incorporation of membrane proteins directly from cells into lipid Salipro nanoparticles. Here, with the pannexin1 channel as a case study, we demonstrate the applicability of this method for structurefunction analysis using SPR and cryo-EM.
Competing Interest Statement
RL, JF and PLG are employed by Salipro Biotech. In addition RL and JF hold shares in Salipro Biotech. ID, ML and MR are employed by Thermo Fisher Scientific. SG and ARG are employed by AstraZeneca.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Posted July 05, 2022.
